Biomerica (BMRA) vs ImmuCell (ICCC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ImmuCell (ICCC) has outperformed Biomerica (BMRA) over the past year, gaining 50.2% versus a loss of 32.7%. Over five years, ICCC leads with a +4.4% price change compared with -95.7% for BMRA. ImmuCell is the larger company by market cap ($87.6 million vs $8.6 million), about 10.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMRA | ICCC |
|---|---|---|
| Share price | $1.88 | $9.65 |
| Market cap | $8.65M | $87.64M |
| 1-day change | -1.05% | -0.41% |
| YTD return | -24.21% | +57.56% |
| 1-year return | -32.75% | +50.23% |
| 5-year return | -95.69% | +4.42% |
| P/E ratio (TTM) | — | 137.86 |
| Forward P/E | 4.82 | — |
| EPS (TTM) | $-1.30 | $0.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.21 | $12.10 |
| 52-week low | $1.45 | $4.52 |
| Distance from 52-week high | -41.43% | -20.25% |
| Average volume | 70.89K | 22.88K |
| Shares outstanding | 4.60M | 9.08M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ImmuCell is about 10.1 times larger than Biomerica by market value ($87.64M vs $8.65M).
- ICCC has outperformed BMRA by 83.0 percentage points over the past year.
BMRA vs ICCC FAQ
Which is bigger, Biomerica or ImmuCell?
ImmuCell (ICCC) is larger, with a market capitalization of $87.64M compared with $8.65M for Biomerica (BMRA).
Which stock has performed better over the past year, BMRA or ICCC?
ICCC returned +50.23% over the past 12 months, compared with -32.75% for BMRA (price return, excluding dividends). Past performance does not predict future results.
Are Biomerica and ImmuCell in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.